Want to see CBIO full AI Analyst Report?
CBIO Stock Chart & Stats
$16.30
$0.94(5.77%)
At close: 4:00 PM EDT
$16.30
$0.94(5.77%)
Day’s Range― - ―
52-Week Range$8.72 - $27.41
Previous CloseN/A
Volume130.39K
Average Volume (3M)145.41K
Market Cap
$625.50M
Enterprise Value$383.42
Total Cash (Recent Filing)$171.59M
Total Debt (Recent Filing)$1.44M
Price to Earnings (P/E)―
Beta1.10
Next Earnings
Nov 05, 2026EPS Estimate
-0.66Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.72
Shares Outstanding37,143,940
10 Day Avg. Volume163,515
30 Day Avg. Volume145,412
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.61
Price to Sales (P/S)11.39
P/FCF Ratio-0.86
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$29.50Price Target Upside80.98% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-2.94
Revenue Forecast (FY)$1.82M
Bulls Say, Bears Say
Bulls Say
Very Low LeverageExtremely low debt provides durable financial flexibility for a R&D-heavy biotech. With minimal interest burden the company can prioritize pipeline spending and strategic options without near-term solvency pressure, reducing the immediacy of refinancing risk over the next 2-6 months.
High Gross Margin Biotech ModelA 100% reported gross margin reflects the structural nature of the business: revenue is not eroded by COGS, so once commercial products or partnerships scale, incremental revenue can meaningfully flow to cover fixed R&D and SG&A. This operating leverage supports long-term margin improvement potential.
Governance Continuity And OversightShareholder support for directors and auditor plus adoption of annual say-on-pay implies stable governance and investor engagement. Consistent board oversight and established audit relationships help sustain strategic continuity and reliable financial reporting during multi-year development cycles.
Bears Say
Substantial Cash BurnVery large negative operating and free cash flow indicate ongoing funding needs; absent a material revenue ramp or cost reduction, the company will likely require capital raises within months. This creates dilution risk and constrains strategic optionality for R&D prioritization over the medium term.
Deep Unprofitability Vs RevenueLosses many times larger than revenue show the business is currently consumption of capital, not a cash-generating enterprise. Until products or high-margin partnerships materialize, negative operating leverage will persist, keeping returns and internal funding prospects weak for 2-6 months.
Eroding Equity CushionDeclining shareholders' equity reflects cumulative losses and reduces the balance-sheet buffer against shocks. A thinner equity base increases vulnerability to future dilution or constrained financing terms, weakening long-term capital stability unless operating losses are curtailed or new capital is secured.
Crescent Biopharma News
CBIO FAQ
What was Crescent Biopharma’s price range in the past 12 months?
Crescent Biopharma lowest stock price was $8.72 and its highest was $27.41 in the past 12 months.
What is Crescent Biopharma’s market cap?
Crescent Biopharma’s market cap is $625.50M.
When is Crescent Biopharma’s upcoming earnings report date?
Crescent Biopharma’s upcoming earnings report date is Nov 05, 2026 which is in 86 days.
How were Crescent Biopharma’s earnings last quarter?
Crescent Biopharma released its earnings results on Jul 30, 2026. The company reported -$0.74 earnings per share for the quarter, missing the consensus estimate of -$0.736 by -$0.004.
Is Crescent Biopharma overvalued?
According to Wall Street analysts Crescent Biopharma’s price is currently Undervalued.
Does Crescent Biopharma pay dividends?
Crescent Biopharma pays a Quarterly dividend of $0.24 which represents an annual dividend yield of N/A. See more information on Crescent Biopharma dividends here
What is Crescent Biopharma’s EPS estimate?
Crescent Biopharma’s EPS estimate is -0.66.
How many shares outstanding does Crescent Biopharma have?
Crescent Biopharma has 37,143,940 shares outstanding.
What happened to Crescent Biopharma’s price movement after its last earnings report?
Crescent Biopharma reported an EPS of -$0.74 in its last earnings report, missing expectations of -$0.736. Following the earnings report the stock price went up 1.693%.
Which hedge fund is a major shareholder of Crescent Biopharma?
Currently, no hedge funds are holding shares in CBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Crescent Biopharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$29.50 (80.98% Upside)
$29.50 (80.98% Upside)
Hedge Fund Trend
Decreased
By 624.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $12.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 11.5%
Last 30 Days ▲ 11.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-20.89%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
16.09%
Trailing 12-Months
Company Description
Crescent Biopharma
Crescent Biopharma, Inc. is a biotechnology firm dedicated to the research and development of novel cancer therapies. Its investigational portfolio notably includes CR-001, a proprietary bispecific antibody engineered to simultaneously target PD-1 and VEGF pathways for the treatment of solid tumors. The company's pipeline further comprises CR-002 and CR-003. Crescent Biopharma also maintains a strategic alliance with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., focusing on the joint advancement and commercialization of oncology therapeutics, encompassing innovative combination approaches. The company's operations are headquartered in Waltham, Massachusetts.
CBIO Stock 12 Month Forecast
Average Price Target
$29.50
▲(80.98% Upside)
Technical Analysis
Compugen
―
Fate Therapeutics
―
Orchestra BioMed Holdings
―
Fractyl Health, Inc.
―
Actuate Therapeutics, Inc.
―
Ownership Overview
11.26% Insiders
5.25% Mutual Funds
2.02% Other Institutional Investors
76.42% Public Companies and
Individual Investors